VTESSE
About Vtesse Vtesse, Inc. is a rare disease company dedicated to developing drugs for patients suffering from diseases that are underserved. The first spin-out company from Cydan Development, Inc., an orphan-drug accelerator that identifies and de-risks programs with therapeutic and commercial potential, Vtesse is working collaboratively with the NIH to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. V... tesse is led by a highly experienced management team that has been involved in the development of more than 20 approved drugs and vaccines. Its experienced consortium of investors, led by New Enterprise Associates, has committed initial funding that is expected to bring this compound through pivotal clinical trials. Vtesse is based in Gaithersburg, Maryland. For more information, visit www.vtessepharma.com.
VTESSE
Industry:
Biotechnology Consumer Research Health Care
Founded:
2014-01-01
Address:
Gaithersburg, Maryland, United States
Country:
United States
Website Url:
http://www.vtessepharma.com
Total Employee:
11+
Status:
Closed
Contact:
(240) 801-9261
Email Addresses:
[email protected]
Total Funding:
42 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Proofpoint
Current Advisors List
Founder
Investors List
Alexandria
Alexandria investment in Series A - Vtesse
Lundbeckfonden Ventures
Lundbeckfonden Ventures investment in Series A - Vtesse
New Enterprise Associates
New Enterprise Associates investment in Series A - Vtesse
Pfizer Venture Investments
Pfizer Venture Investments investment in Series A - Vtesse
Bay City Capital
Bay City Capital investment in Series A - Vtesse
Lundbeckfonden Ventures
Lundbeckfonden Ventures investment in Series A - Vtesse
New Enterprise Associates
New Enterprise Associates investment in Series A - Vtesse
Pfizer Venture Investments
Pfizer Venture Investments investment in Series A - Vtesse
Bay City Capital
Bay City Capital investment in Series A - Vtesse
Alexandria
Alexandria investment in Series A - Vtesse
Newest Events participated
Participated in Bett Show 2016
on 2016-01-20 as exhibitor
Official Site Inspections
http://www.vtessepharma.com
- Host name: actharstartform.com
- IP address: 146.214.96.100
- Location: St Louis United States
- Latitude: 38.6249
- Longitude: -90.4496
- Metro Code: 609
- Timezone: America/Chicago
- Postal: 63131
More informations about "Vtesse"
Vtesse - Crunchbase Company Profile & Funding
Vtesse, Inc. is a rare disease company dedicated to developing drugs for patients suffering from diseases that are underserved. The first spin-out company from Cydan Development, Inc., an …See details»
Vtesse Company Profile - Office Locations, Competitors ... - Craft
Vtesse is based in Gaithersburg, Maryland. See insights on Vtesse including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Vtesse Company Profile | Management and Employees List
Vtesse, Inc. is a rare disease company dedicated to developing drugs for patients suffering from diseases that are underserved.See details»
Vtesse, Inc. - Bay City Capital
Vtesse, Inc. is a rare disease company dedicated to developing drugs for patients suffering from diseases that are under-served.See details»
Vtesse Company Profile 2024: Valuation, Investors, Acquisition
Developer of new drug treatments designed to treat severe and life-threatening diseases. The company's new drug treatments, includes treatment for rare disease Niemann-Pick Disease …See details»
FOR IMMEDIATE RELEASE Vtesse, Inc. Announces FDA’s Granting …
Gaithersburg, MD, January 6, 2016 – Vtesse, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted its drug candidate, VTS-270 for treatment of Niemann-Pick …See details»
Vtesse Pharma - The Lundbeck Foundation
Developed VTS-270 to treat patients with Niemann-Pick Disease Type C. The Lundbeck Foundation annually distributes more than DKK 500 mio. to Danish-based healthcare science …See details»
New Rare Disease Company Vtesse, Inc. Launches with $25M
Jan 7, 2015 · Vtesse is the first spin-off company for Cydan Development, Inc., an orphan-drug accelerator that shares with Vtesse the same syndicate of leading life sciences investors that …See details»
FOR IMMEDIATE RELEASE Medicines and Healthcare Products
Aid Paul Gissen, PhD, MRCPCH, Great Ormond Street Hospital, who is an investigator in Vtesse’s Phase 2b/3 clinical trial of VTS-270. “The MHRA’s PIM designation is based on three …See details»
Vtesse, Inc. Expands Scientific Advisory Board and Appoints New …
Oct 22, 2015 · Today's news comes on the heels of Vtesse's recent announcement that Rush University Medical Center has enrolled three patients in its pivotal Phase 2b/3 clinical trial with …See details»
Vtesse Announces Appointment of Jason Meyenburg as Chief …
“As we near completion of enrollment in our pivotal Phase 2b/3 clinical trial of our lead drug candidate, VTS-270, our primary goal is to advance regulatory submissions. Assuming we …See details»
Biotech startup Vtesse granted FDA breakthrough designation for …
Jan 6, 2016 · Biotech startup Vtesse on Wednesday announced the FDA has granted a breakthrough therapy designation to its lead drug candidate VTS-270 for treatment of …See details»
Vtesse, Inc. | Insights
Dec 27, 2017 · Impact Biomedicines has closed a structured financing for up to $90m – just two weeks after launching with $22.5m in venture capital – that will support commercialization of …See details»
Vtesse, Inc. Announces FDA’s Granting of Breakthrough Therapy ...
The FDA grants Breakthrough Therapy designation to companies to help accelerate development and review of drug candidates when preliminary clinical evidence indicates that the drug may …See details»
Vtesse, Inc. Expands Scientific Advisory Board, Fills Key Patient ...
GAITHERSBURG, Md., June 15, 2015 /PRNewswire/ -- Vtesse, Inc., a rare disease company focused on developing drugs for Niemann-Pick Disease Type C (NPC) and other severe …See details»
Vtesse, Inc. Announces FDA's Granting of Breakthrough Therapy ...
GAITHERSBURG, Md., Jan. 6, 2016 /PRNewswire/ -- Vtesse, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted its drug candidate, VTS-270 for treatment of …See details»
Vtesse Completes Enrollment of Phase 2b/3 Pivotal Clinical Trial of …
Mar 15, 2017 · Vtesse, Inc. is a rare disease company dedicated to developing drugs for patients suffering from underserved diseases. Vtesse closely collaborates with National Institutes of …See details»
Vtesse, Inc. (Vtesse, Inc.) - 药物管线_专利_临床试验_投融营收
This is a Phase-2, multicenter, multiple dose, open-label, 2-part evaluation study which will primarily assess the safety and tolerability of VTS-270 (2-hydroxypropyl beta-cyclodextrin [HP …See details»
Sucampo Pharmaceuticals Acquires Vtesse For $200 ... - Seeking …
Apr 10, 2017 · Summary. Sucampo has acquired orphan drug developer Vtesse for $200 million in upfront consideration. Vtesse is in pivotal trials for its treatment for Niemann-Pick Disease …See details»
Share this article - PR Newswire
GAITHERSBURG, Md., July 25, 2016 /PRNewswire/ -- Vtesse, Inc., a company committed to developing drugs that will benefit patients with extremely rare, life-threatening diseases, …See details»